ArticleJournal of the American Heart Association2022

Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.

Maya S Sheth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.